Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

The pharmaco-microbiomics of depression

Obiettivo

This interdisciplinary project aims to improve response to depression treatment using the gut microbiota. About one third of patients with depression do not respond to treatment with Selective-Serotonin-Reuptake-Inhibitors (SSRIs). Moreover, side effects such as gastrointestinal complaints are common.

The commensal gut microbiota, residing in the human intestinal tract in trillions, likely contribute to variation in treatment efficacy. This makes them a promising candidate to improve treatment response. The highly inter-individual variable gut bacteria collectively represent an enormous amount of genes, enzymes and transporters (outnumbering human genes by 10-100 times). Hereby, the gut microbiota are involved in processing of orally ingested compounds, and, through the communication highway called the gut-brain-axis, interact with the central nervous system. Anti-depressant medication such as SSRIs reduce gut microbial diversity and change community dynamics. For example, in vitro studies have shown unintentional effects of SSRIs in the gut on a bacterium with a human-analogous serotonin transporter. This negatively affects serotonin metabolism in the gut, potentially contributing to side effects and reduced treatment response. Other similar mechanisms may occur, yet very limited experimental experimental data exist mapping which and how gut microbiota are impacted by SSRIs. Moreover, hardly any studies link SSRI medication induced gut microbial effects to treatment response.

Using clinical cohorts, I will dissociate gut microbial profiles of patients responding versus not responding to their SSRI medication. In a culturing experiment, fecal material of such responders and non-responders will be characterized in terms of growth profile after SSRI exposure, transcriptomic and metabolomics. Using these results, a probiotics product will be developed. This project contains clinical, microbial and applied work with great societal and economic potential.

Campo scientifico (EuroSciVoc)

Parole chiave

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) HORIZON-MSCA-2021-PF-01

Vedi tutti i progetti finanziati nell’ambito del bando

Coordinatore

JOHANN WOLFGANG GOETHE-UNIVERSITAET FRANKFURT AM MAIN
Contributo netto dell'UE
€ 237 109,20
Indirizzo
THEODOR W ADORNO PLATZ 1
60323 Frankfurt Am Main
Germania
Regione
Hessen Darmstadt Frankfurt am Main, Kreisfreie Stadt
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
Nessun dato

Partner (2)